A study led by Mount Sinai School of Medicine researchers of 192 pharmaceutical advertisements (83 full unique advertisements) in biomedical journals found that only 18 percent (15) were compliant with Food and Drug Administration (FDA) guidelines, and over half failed to quantify serious risks including death.
Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?
Prescription Medicines Code of Practice Authority Issues Social Media Guidance for Pharma. The Brits have won the race to issue social media guidance for the drug industry! In April, 2011, the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the self-regulatory code of the Association of the British Pharmaceutical Industry (ABPI), published 'informal guidance' providing the drug industry advice on how to use online communications.
This article summarizes the results of a survey of physicians designed to assess the value of various adherence solutions -- including HealthPrize -- and the potential of these solutions to influence physicians' prescribing behavior.
Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.
Welcome to Volume 10, Issue #15 (12 OCTOBER 2011) of Pharma Marketing News.
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.